---
schema_version: "secwatch.filing_event.v1"
accession: "0001664710-25-000015"
form_type: "8-K"
ticker: "KROS"
cik: "0001664710"
company_name: "Keros Therapeutics, Inc."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:40:41.246703+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Keros Therapeutics Q4 2024 net loss $46.0M; receives $200M Takeda upfront for elritercept

## Summary
- Net loss of $46.0M in Q4 2024 vs $40.2M in Q4 2023; full-year net loss $187.4M.
- Revenue of $3.0M in Q4 2024 vs $0.1M in prior period, largely from Hansoh milestone.
- Cash and equivalents $559.9M at Dec 31, 2024; plus $200M Takeda upfront payment received Feb 2025 extends runway into 2029.
- Phase 1 data for KER-065 expected in Q1 2025; Phase 2 TROPOS trial data for cibotercept (KER-012) planned.
- R&D expenses rose to $45.6M in Q4 2024, driven by elritercept Phase 3 and TROPOS trial.

## SEC filing metadata
- accession: 0001664710-25-000015
- form_type: 8-K
- ticker: KROS
- cik: 0001664710
- company_name: Keros Therapeutics, Inc.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000015/0001664710-25-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1664710/000166471025000015/kros-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001664710-25-000015
- JSON: https://secwatch.observer/filing/0001664710-25-000015.json
- Plain text: https://secwatch.observer/filing/0001664710-25-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.